Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today announced data from its OSPREY 2301 Study of PyLTM (18F-DCFPyL). PyL is the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments Trading Halts

Progenics Pharma (PGNX) to Resume Trading at 8 am ETOctober 5, 2018 7:39 AM Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate CancerOctober 5, 2018 7:30 AM Progenics Pharma (PGNX) Halted, News PendingOctober 5, 2018 7:25 AM